IJC Heart & Vasculature 9 (2015) 85–88

Contents lists available at ScienceDirect

IJC Heart & Vasculature

journal homepage: http://www.journals.elsevier.com/ijc-heart-and-vasculature

Clinical predictors of inducible sustained ventricular tachycardia during electrophysiologic study in patients with chronic Chagas' heart disease

Augusto Cardinalli-Neto [a], Adalberto M. Lorga-Filho [a], Elissandro F. Silva [a], Renata P. Lima [a], Eduardo Palmegiani [a], Reinaldo B. Bestetti [b,*]

[a] Department of Cardiology and Cardiovascular Surgery, Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil
[b] Post-Graduate Division of São José do Rio Preto Medical School, São José do Rio Preto, Brazil

ARTICLE INFO

Article history:
Received 14 August 2015
Received in revised form 14 October 2015
Accepted 16 October 2015
Available online 19 October 2015

Keywords:
Chagas' disease
Trypanosoma cruzi
Electrophysiologic study
Arrhythmias
Amiodarone
Arrhythmias

ABSTRACT

Background: Clinical independent predictors of inducible sustained ventricular tachycardia (VT) during electrophysiologic study (EPS) are not known in patients with chronic Chagas' heart disease. The purpose of this investigation was to fill this gap.
Methods: The medical charts of 47 patients with a positive serology for Chagas' disease who had undergone EPS between September 2006 and July 2012 at our institution were reviewed. Reasons for the EPS were the presence of unexplained syncope, non-sustained ventricular tachycardia (NSVT) on either resting ECG or 24 h-Holter monitoring as well as a LVEF < 55% and >35% at echocardiography. A stepwise logistic regression analysis was performed to identify noninvasive predictors of inducible sustained VT/ventricular fibrillation during EPS.
Results: On univariate analysis, syncopal episodes ($p = 0.04$), amiodarone therapy ($p < 0.005$), diastolic blood pressure ($p = 0.03$), creatinine serum levels ($p < 0.001$), potassium serum levels ($p < 0.001$), and lengthening of the QRS complex ($p = 0.03$) were associated with inducible sustained VT during EPS. In the multivariate model, amiodarone therapy ($p = 0.03$; hazard ratio = 10; Wald coefficient = 4.5; 95% confidence interval 1.2 to 85.2) was the only variable retained as independent predictor of inducible sustained VT during EPS.
Conclusion: Amiodarone therapy was the only independent variable associated with sustained VT inducibility during EPS in patients with chronic Chagas' heart disease.

1. Introduction

Chagas' disease affects about 10 million people in Latin America, another 25 million are at risk of acquiring the disease, and about 10,000 people die of the disease annually. Chagas' disease has become global as a result of international immigration, about 750,000 people with chronic Chagas' disease are living outside South America, mainly in the United States and Europe [1]. As a result, the world economic burden of Chagas' disease is US$ 7.9 billion annually, higher than that seen in cervical or oral cancer, and affects the economy of both endemic and non-endemic countries [2].

The disease is caused by the protozoan *Trypanosoma cruzi*, it is transmitted to humans by eye mucosa or skin lesion contact with the feces of sucking-bugs. However, other sources of transmission, like oral transmission, have become important nowadays. Initial infection occurs in early infancy, but the clinical manifestations of Chagas' cardiomyopathy, which affects about 30% of infected patients, appear up to 20 years later [3]. Chagas' cardiomyopathy manifests by chronic systolic heart failure (CHF) [4], thromboembolism [3], malignant ventricular arrhythmias [5,6], and sudden cardiac death (SCD) [7].

SCD affects about 5% of the general, unselected population with chronic Chagas' disease [7]. It is the mode of death in 17 to 50% of patients with this condition [8,9], and afflicts patients with overt chronic Chagas' heart disease [10], particularly those with ventricular dysrhythmias on the 12-lead ECG and mild to moderate left ventricular systolic dysfunction [11]. In the vast majority of cases, SCD is caused by sustained ventricular tachycardia (VT) degenerating into ventricular fibrillation (VF) or VF itself [7].

An electrophysiologic study (EPS) is useful for identifying chronic Chagas' disease patients at high risk of SCD. In fact, patients with chronic Chagas' heart disease in whom sustained VT/VF are induced during EPS have a higher risk of SCD in comparison to those in whom such malignant arrhythmias are not induced [12]. EPS is not widely available and impractical to be offered to millions of people. Nonetheless, it would be of interest to predict on clinical grounds which patients will develop sustained VT/VF during EPS. This might be used as means of selecting patients for EPS. Accordingly, the present study was undertaken in

* Corresponding author at: Rua Jerônimo Panazollo, 434, 14096-430 Ribeirão Preto, Brazil.
E-mail address: rbestetti44@gmail.com (R.B. Bestetti).

http://dx.doi.org/10.1016/j.ijcha.2015.10.001

an attempt to determine clinical predictors of inducible sustained VT during EPS.

2. Methods

2.1. Patients

The medical charts of patients with a positive serology for Chagas' disease who had undergone EPS between September 2006 and July 2012 at our institution were considered for the study. Inclusion criteria were an EPS performed for the following reasons: unexplained syncope, non-sustained ventricular tachycardia (NSVT) on either resting ECG or 24 h-Holter monitoring as well as a LVEF < 55% and >35% at echocardiography. The diagnostic work-up, besides the EPS, consisted of history-taken and physical examination at presentation, 12-lead ECG, standard laboratory tests, and 2-D echocardiography. The New York Heart Association Functional Class, heart rate, systolic and diastolic blood pressure were noted on study admission.

All patients with left ventricular systolic dysfunction were treated with beta-blockers and angiotensin converting enzyme inhibitors/angiotensin receptor block (ACEI/ARB) at target or maximal tolerated doses. Those with systemic and pulmonary congestion received diuretics and/or digitalis when appropriated. Patients were given amiodarone at the discretion of the referral doctor. Overall, 39 (83%) patients were on ACEI/ARB, 36 (76%) on beta-blockers at target or maximal tolerated daily dose, and 24 (51%) on diuretics. Seventeen (35%) patients received treatment with spironolactone, and 14 (29%) were on amiodarone. Mean daily dose of enalapril was 18.7 ± 10.2 mg, mean daily dose of captopril 70.7 ± 19.8 mg, mean daily dose of losartan 45.4 ± 10.1 mg, mean daily dose of carvedilol 26 ± 18 mg, mean daily dose of atenolol 37.2 ± 17.7 mg, mean daily dose of digoxin 0.12 ± 0 mg, and mean daily dose of amiodarone 278.6 ± 112.2 mg. Such medications were maintained at the time of EPS.

During the EPS, ventricular stimulation was performed only in the right ventricular apex, using 3 extra-stimuli with up 200 ms interval at most. The cycle length of extra stimuli were 600, 500 and 430 ms, respectively.

2.2. Statistical analysis

Continuous variables are shown as mean ± standard deviation, whereas categorical variables are presented as percentages. Continuous variables between inducible and non-inducible SVT groups were compared using the unpaired T Test, while categorical variables between both groups were compared by the χ-square test. Differences between variables at the level of $p < 0.05$ were entered in stepwise logistic regression analysis to identify noninvasive predictors of inducible sustained VT/VF during EPS.

The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology: Shewan LG and Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1–2.

3. Results

A total of 47 patients fulfilled the inclusion criteria and were entered in the study. During EPS, sustained VT was induced in 12 (25%) of 47 patients. By contrast, VF was induced in none of the patients. Table 1 lists the clinical characteristics of patients with inducible and non-inducible sustained VT during EPS. Table 2 depicts electrocardiographic and echocardiographic variables in both patients' groups. Also, the AH interval was 94.4 ± 25.8 ms in patients with and 98 ± 48.7 ms in patients with no inducible sustained VT ($p > 0.05$), while the HV interval was 55.4 ± 13.5 ms in patients with sustained VT and 57.6 ± 26.3 ms ($p > 0.05$) in patients with no inducible sustained VT. The cycle length of inducible sustained VT was 309 ± 49 ms. The episodes of sustained VT were treated with cardioversion in 4 (33%) out of 12 patients, and a burst of ventricular stimulation in 7 (58%) out of 12 patients. One episode of inducible sustained VT terminated spontaneously.

On univariate analysis, history of syncopal episodes ($p = 0.04$), amiodarone therapy ($p < 0.005$), diastolic blood pressure ($p = 0.03$), creatinine serum levels ($p < 0.001$), potassium serum levels ($p < 0.001$), and lengthening of the QRS complex during EPS ($p = 0.03$) were associated with inducible sustained VT during EPS. In the multivariate model, however, amiodarone therapy ($p = 0.03$; hazard ratio = 10; Wald coefficient = 4.5; 95% confidence interval 1.2 to 85.2) was the only variable retained as an independent predictor of inducible sustained VT during EPS.

Table 1
Clinical and laboratory characteristics of a cohort of patients with chronic Chagas' heart disease with inducible or no inducible sustained ventricular tachycardia during electrophysiologic study.

Variables	SVT (n = 12)	No SVT (n = 35)
Age (years)	57 ± 9	57 ± 12
Male	8 (67%)	21 (60%)
NYHA III/IV	1 (8%)	6 (17%)
Syncope	9 (75%)	13 (37%)*
ACEI/ARB	10 (83%)	29 (83%)
Beta-blockers	7 (58%)	29 (83%)
Digoxin	3 (25%)	9 (26%)
Diuretic	6 (50%)	18 (51%)
Spironolactone	6 (50%)	11 (31%)
Amiodarone	8 (67%)	6 (17%)**
Heart rate	66 ± 11	69 ± 13
SBP (mmHg)	113.6 ± 13.6	127.3 ± 24.9
DBP (mmHg)	70.9 ± 8.3	80.3 ± 13.1***
Sodium (mEq/L)	138.9 ± 5	140.4 ± 2.9
Potassium (mEq/L)	4.1 ± 0.2	4.3 ± 0.4
Creatinine (mg/dL)	1.1 ± 0.3	1.3 ± 0.5**
Hemoglobin (g/dL)	13.6 ± 0.8	13.6 ± 1.7

SVT = sustained ventricular tachycardia; ACE/ARB = angiotensin converting enzyme inhibitor/angiotensin receptor block; SBP = systolic blood pressure; DBP = diastolic blood pressure.
* p = 0.04.
** p < 0.005.
*** p = 0.03.

Table 2
Electrocardiographic findings and echocardiographic features in patients with chronic Chagas' heart disease with inducible or no inducible malignant arrhythmias during electrophysiologic study.

Variables	SVT (n = 12)	No SVT (n = 35)
Atrial fibrillation	1 (8%)	7 (20%)
Pacemaker	3 (25%)	6 (17%)
Left bundle branch block	0 (0%)	5 (14%)
LAFB	3 (25%)	13 (37%)
RBBB	3 (25%)	16 (46%)
Low QRS voltage	0 (0%)	1 (3%)
VPC	4 (33%)	4 (11%)
NSVT	10 (83%)	21 (60%)
QRS duration (ms)	142 ± 37.1	137.9 ± 28***
LVDD (mm)	60.1 ± 9.2	58.1 ± 9
LVSD (mm)	46.2 ± 10.3	43.4 ± 12.4
Right ventricle (mm)	21.1 ± 5.2	23.8 ± 6.7
SWMA	2 (17%)	4 (11%)
LVEF (%)	45.8 ± 13.2	53.1 ± 15.7

SVT = sustained ventricular tachycardia; LFAB = left anterior fascicular block; RBBB = right bundle branch block; VPC = ventricular premature contractions; NSVT = non-sustained ventricular tachycardia; LVDD = left ventricular diastolic diameter; LVSD = left ventricular systolic diameter; SWMA = systolic wall motion abnormalities; LVEF = left ventricular ejection fraction.
*** p = 0.03.